The European Medicines Agency (EMA) said it is analyzing women’s representation in clinical trials as part of a wider effort to embed women’s health considerations into medicines development and regulation. The initiative targets representation within trial populations, aligning regulatory attention with persistent enrollment imbalances reported across therapeutic areas. The EMA’s assessment is expected to feed into how trial data are interpreted and how expectations are set for future studies under the EU regulatory framework. For developers, the announcement increases the likelihood that trial design, endpoints, and subgroup analyses will face sharper scrutiny around gender. For the industry, the EMA move adds to a growing regulatory focus on how real-world demographics map onto clinical evidence—particularly where dosing, safety, or disease presentation may differ by sex and gender.